Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Nov 1;35(7):590-597.
doi: 10.1097/MCA.0000000000001417. Epub 2024 Aug 23.

Ticagrelor monotherapy after short duration of dual antiplatelet therapy compared to continued dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions: an updated meta-analysis

Zeeshan Mansuri  1 , Hadiah Ashraf  2 , Thahsin Taikadan  3 , Gokul Rajith  4 , Ayesha Ayesha  5 , Urooj Fatima  6 , Gabriel Erzinger  7
Affiliations
Meta-Analysis

Ticagrelor monotherapy after short duration of dual antiplatelet therapy compared to continued dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions: an updated meta-analysis

Zeeshan Mansuri et al. Coron Artery Dis. .

Abstract

Background: The optimum duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) remains controversial. Ticagrelor monotherapy after short duration of DAPT (1-3 months) is a subject of research. We conducted an updated systematic review and meta-analysis comparing the ticagrelor monotherapy with continued DAPT after short duration of DAPT in patients with ACS undergoing PCI.

Methods: PubMed, Embase, and Cochrane databases were searched for studies comparing ticagrelor monotherapy to DAPT after PCI and reported the outcomes of major adverse cardiovascular and cerebrovascular events (MACCE); net adverse clinical events (NACE); myocardial infarction (MI); major bleeding; death from any cause; definite or probable stent thrombosis; and target vessel revascularization (TVR). Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Statistical analysis was performed using Review Manager (Cochrane collaboration). Heterogeneity was examined with I2 test.

Results: Of 3,208 results, five studies with 21,407 patients were included of which 50% received ticagrelor monotherapy. Studies had reported follow up of 12 months. Major bleeding [hazard ratio 0.47; 95% confidence interval (CI), 0.37-0.61; P < 0.001], NACE (hazard ratio 0.71; 95% CI, 0.56-0.90; P = 0.005), and all-cause death (hazard ratio 0.76; 95% CI, 0.59-0.98; P = 0.04) were significantly less with ticagrelor monotherapy. Other outcomes were comparable in both groups.

Conclusion: In patients with ACS undergoing PCI, ticagrelor monotherapy reduces major bleeding, NACE and all-cause death as compared to continued DAPT for 12 months. Major ischemic outcomes were similar. Ticagrelor monotherapy is the way forward after short duration of DAPT after PCI in ACS.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79:e21–e129.
    1. Brodie BR, Garg A, Stuckey TD, Kirtane AJ, Witzenbichler B, Maehara A, et al. Fixed and modifiable correlates of drug-eluting stent thrombosis from a large all-comers registry: insights from ADAPT-DES. Circ Cardiovasc Interv. 2015; 8:e002568.
    1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045–1057.
    1. Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial. JAMA Cardiol 2019; 4:1092–1101.
    1. Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J 2020; 41:3533–3545.

MeSH terms